key: cord-0832944-lk50jq7o authors: Martone, Giulia M.; Nanjireddy, Priyanka M.; Craig, Robin A.; Prout, Andrew J.; Higman, Meghan A.; Kelly, Kara M.; Ambrusko, Steven J. title: Acute hepatic encephalopathy and multiorgan failure in sickle cell disease and COVID‐19 date: 2021-01-23 journal: Pediatr Blood Cancer DOI: 10.1002/pbc.28874 sha: b9c98e8477a8d72faa277891db4316166076954c doc_id: 832944 cord_uid: lk50jq7o nan Four weeks later, she was re-hospitalized with anorexia, fatigue, and worsening abdominal pain. She received analgesics (ketorolac, morphine) and continued home medications including DFX; repeat SARS-CoV2 PCR negative. Fever developed on hospital day 3; blood culture was obtained, and ceftriaxone was administered. She became acutely encephalopathic 5 h later without focal neurologic deficit. MOFS is a known catastrophic SCD complication; however, this case with severe encephalopathy secondary to acute liver failure with hyperammonemia and neurologic insult is unusual. Often fatal without prompt RBCX, SCD-MOFS typically evolves from VOC progressing to fever, altered sensorium, rapid significant anemia and thrombocytopenia, and acute liver, kidney, and/or respiratory failure. 8, 9 While she had some classic features of SCD-MOFS, hyperammonemia is not typical, and anemia and thrombocytopenia were mild. While her low baseline hemoglobin S (HbS) (<30%) is not fully protective, it suggests that MOFS was not only because of SCD. Her acute and chronic liver disease-iron overload, history of hepatic crisis, 10,11 potential hydroxychloroquine, or DFX-toxicity 12,13predispose to hepatic injury 14 ; however, these are unlikely the sole cause. Acute liver failure differential included acute SCD hepatopathy, which could be acute hepatic crisis, hepatic sequestration, or acute intra-hepatic cholestasis. Though chronic RBCX maintained low HbS, this may not fully protect against hepatopathy. 7,10 Other organ involvement and hyperammonemia preceding increased AST/ALT argue against SCD hepatopathy alone. DFX-induced liver failure and hyperammonemia are reported; however, her MOFS with hyperinflammation suggests cause beyond DFX toxicity alone. 8, 9 Despite negative SARS-CoV-2 PCR immediately prior to MOFS, the short duration from COVID-19 to MOFS is suggestive. Severe COVID- Vaso-occlusive crisis and acute chest syndrome in sickle cell disease due to 2019 novel coronavirus disease (COVID-19) COVID-19 cytokine storm: the interplay between inflammation and coagulation Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study MMWR-hospitalization rates and characteristics of patients hospitalized with laboratory-confirmed coronavirus disease 2019-COVID-NET, 14 States A comparative study on the clinical features of COVID-19 pneumonia to other pneumonias Reversal of severe multiorgan failure associated with sickle cell crisis using plasma exchange: a case series Therapeutic plasma exchange in children with thrombocytopenia-associated multiple organ failure Catastrophic multi-organ failure with bone marrow necrosis in a sickle cell beta plus thalassemia patient Red cell exchange: special focus on sickle cell disease Sickle cell hepatopathy Hepatobiliary complications in children with sickle cell disease: a retrospective review of medical records from 616 Patients Acute liver failure during deferasirox chelation: a toxicity worth considering Fulminant liver failure in a child with b-thalassemia on deferasirox: a case report Acute and chronic hepatobiliary manifestations of sickle cell disease: a review Kawasaki-like multisystem inflammatory syndrome in children during the covid-19 pandemic in Paris, France: prospective observational study COVID-19 and its implications for thrombosis and anticoagulation Gastrointestinal manifestations of SARS-CoV-2 infection and virus load in fecal samples from the Hong Kong cohort and systematic review and meta-analysis Potential effect of blood purification therapy in reducing cytokine storm as a late complication of critically ill COVID-19 A novel treatment approach to the novel coronavirus: an argument for the use of therapeutic plasma exchange for fulminant COVID-19